bioAffinity Technologies (NASDAQ:BIAF) Raised to “Hold” at Wall Street Zen

bioAffinity Technologies (NASDAQ:BIAF) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

bioAffinity Technologies Price Performance

BIAF opened at $3.92 on Friday. The firm has a market cap of $17.64 million, a price-to-earnings ratio of -0.25 and a beta of -0.82. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.58 and a current ratio of 2.60. The firm’s 50-day simple moving average is $1.84 and its 200-day simple moving average is $2.00. bioAffinity Technologies has a twelve month low of $0.69 and a twelve month high of $25.83.

bioAffinity Technologies (NASDAQ:BIAF) last released its quarterly earnings results on Saturday, March 14th. The company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.70) by $1.59. The firm had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.55 million. bioAffinity Technologies had a negative return on equity of 301.67% and a negative net margin of 241.93%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BIAF. Sabby Management LLC bought a new stake in bioAffinity Technologies in the third quarter valued at approximately $719,000. Geode Capital Management LLC bought a new position in shares of bioAffinity Technologies during the fourth quarter worth $36,000. Finally, Scientech Research LLC bought a new position in shares of bioAffinity Technologies during the third quarter worth $49,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.